Most recently, PAX8 and PAX2 have shown improved RCC-specificity over the traditionally used RCC markers CD10 and RCC monoclonal antibody, although several female genital tract and thyroid tumors stain positive for both markers [7, 8]. This evidence concerns the gene PAX8 and renal cell carcinoma.